menu

Menopause Matters…Let’s Start Paying Attention to Racial and Ethnic Differences: Addressing Patient Needs

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Menopause Matters…Let’s Start Paying Attention to Racial and Ethnic Differences: Addressing Patient Needs

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.

    Addressing Patient Needs
    The faculty panel discusses the selection of therapy to meet unmet clinical needs across diverse women facing the menopause transition.

  • Provider(s)/Educational Partner(s)

    This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy.

  • Commercial Support

    Supported by an educational grant from Astellas.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Outline how women of different races/ethnicities have varying menopausal experiences that negatively impact quality of life and health status.
    • Describe current unmet needs that contribute to undertreatment of vasomotor symptoms in women of color.
    • Apply tactics to improve culturally competent shared decision making (SDM) for menopausal women.
  • Target Audience

    This activity is intended for obstetricians/gynecologists, primary care providers and endocrinologists treating women going through menopause, including physicians, nurses, nurse practitioners, and physician assistants. 

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Karen Catino at kcatino@achlcme.org

  • Accreditation and Credit Designation Statements

    Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Purdue University College of Pharmacy designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Purdue University College of Pharmacy requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies . All relevant financial relationships have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Risa Kagan, MD, FACOG  
    Consulting Agreements: Amgen, Astellas, Cooper Surgical, TherapeuticsMD, Inc. 
    DSMB: Astellas
    Advisory Board: Pfizer, Synexis
    Editorial Board: Menopause Journal

    Ekta Kapoor, MBBS
    Sources of Funding for Grants/Research: Mithra Pharmaceuticals
    Consulting Agreements: Astellas Pharmaceuticals, Mithra Pharmaceuticals, Womaness
    Principal Investigator:  Mithra Pharmaceuticals 

    Genevieve Neal-Perry, MD, PhD
    Sources of Funding for Grants/Research: Astellas Pharmaceuticals, Merck Pharmaceuticals, National Institutes of Health-Women’s Reproductive Health Research

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of SSRI/SNRIs and investigational neurokinin receptor antagonists

  • Staff and Reviewer Disclosures

    Purdue University College of Pharmacy, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Disclaimer

    The content for this activity was developed independently of the ineleigble company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Purdue College of Pharmacy requires the speaker to disclose that a product is not labeled for the use under discussion.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion.

    Addressing Patient Needs
    The faculty panel discusses the selection of therapy to meet unmet clinical needs across diverse women facing the menopause transition.

  • Provider(s)/Educational Partner(s)

    This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy.

  • Commercial Support

    Supported by an educational grant from Astellas.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Outline how women of different races/ethnicities have varying menopausal experiences that negatively impact quality of life and health status.
    • Describe current unmet needs that contribute to undertreatment of vasomotor symptoms in women of color.
    • Apply tactics to improve culturally competent shared decision making (SDM) for menopausal women.
  • Target Audience

    This activity is intended for obstetricians/gynecologists, primary care providers and endocrinologists treating women going through menopause, including physicians, nurses, nurse practitioners, and physician assistants. 

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Karen Catino at kcatino@achlcme.org

  • Accreditation and Credit Designation Statements

    Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Purdue University College of Pharmacy designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Purdue University College of Pharmacy requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies . All relevant financial relationships have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Risa Kagan, MD, FACOG  
    Consulting Agreements: Amgen, Astellas, Cooper Surgical, TherapeuticsMD, Inc. 
    DSMB: Astellas
    Advisory Board: Pfizer, Synexis
    Editorial Board: Menopause Journal

    Ekta Kapoor, MBBS
    Sources of Funding for Grants/Research: Mithra Pharmaceuticals
    Consulting Agreements: Astellas Pharmaceuticals, Mithra Pharmaceuticals, Womaness
    Principal Investigator:  Mithra Pharmaceuticals 

    Genevieve Neal-Perry, MD, PhD
    Sources of Funding for Grants/Research: Astellas Pharmaceuticals, Merck Pharmaceuticals, National Institutes of Health-Women’s Reproductive Health Research

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of SSRI/SNRIs and investigational neurokinin receptor antagonists

  • Staff and Reviewer Disclosures

    Purdue University College of Pharmacy, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Disclaimer

    The content for this activity was developed independently of the ineleigble company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Purdue College of Pharmacy requires the speaker to disclose that a product is not labeled for the use under discussion.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule6 Dec 2022